Alerta

USE OF POSTBIOTICS FOR TREATING OR PREVENTING DISRUPTIONS OF THE GUT-BRAIN AXIS

Resumen de: WO2025217259A1

Provided herein are postbiotic compositions prepared using fermentation and herbal substrate compositions for the treatment or prevention of the disruption of the gut-brain axis. Such postbiotic compositions can be used to treat or prevent neurological diseases or disorders, such as synucleinopathies, including but not limited to Parkinson's disease.

NEUROACTIVE STEROID FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Resumen de: US2025319105A1

The present disclosure relates to compositions, kits and methods of treating Alzheimer's disease comprising administering an NMD A receptor positive allosteric modulator or a CYP46A1 inhibitor.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUNTINGTON’S DISEASE AND HTT PROTEINOPATHIES

Resumen de: US2025319073A1

The present disclosure provides compounds, compositions, and/or methods for treating, preventing, inhibiting, amelio-rating, or delaying the onset of Huntington's disease and/or a HTT proteinopathy in a subject. The methods can comprise administering to the subject an effective amount of a peptidomimetic compound, such as (R)-2-amino-N—((S)-1-(((S)-5-amino-1-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-yl)-5- guanidinopentanamide, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and/or solvate thereof, alone or in combination with one or more other therapeutic agents.

1H-PYRROLO2,3-BPYRIDIN-4-YL-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES

Resumen de: AU2024253757A1

This disclosure relates to compounds of Formula (I-1) or (I-2): The compounds of the present disclosure are capable of inhibiting the activity of tyrosine kinase 2 (TYK2) and are useful for the treatment of diseases or disorders, such as e.g. inflammation, autoimmune disease, neuroinflammation, arthritis, rheumatoid arthritis, spondyloarthropathies, systemic lupus erythematous, lupus nephritis, arthritis, osteoarthritis, gouty arthritis, pain, fever, pulmonary sarcoisosis, silicosis, cardiovascular disease, atherosclerosis, myocardial infarction, thrombosis, congestive heart failure and cardiac reperfusion injury, cardiomyopathy, stroke, ischaemia, reperfusion injury, brain edema, brain trauma, neurodegeneration, liver disease, inflammatory bowel disease, Crohn's disease, ulcerative colitis, nephritis, retinitis, retinopathy, macular degeneration, glaucoma, diabetes (type 1 and type 2), diabetic neuropathy, viral and bacterial infection, myalgia, endotoxic shock, toxic shock syndrome, autoimmune disease, osteoporosis, multiple sclerosis, endometriosis, menstrual cramps, vaginitis, candidiasis, cancer, fibrosis, obesity, muscular dystrophy, polymyositis, dermatomyositis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, vitiligo, alopecia, Alzheimer's disease, skin flushing, eczema, psoriasis, atopic dermatitis and sunburn. The disclosure further provides methods of preparing the compounds.

Carbidopa and L-dopa prodrugs and their use to treat Parkinson's disease

Resumen de: AU2025238004A1

CARBIDOPA AND L-DOPA PRODRUGS AND THEIR USE TO TREAT PARKINSON'S DISEASE Abstract The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease. CARBIDOPA AND L-DOPA PRODRUGS AND THEIR USE TO TREAT PARKINSON'S DISEASE Abstract The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease. ep - ' e p b s t r a c t h e p r e s e n t d i s c l o s u r e r e l a t e s t o ( a ) c a r b i d o p a p r o d r u g s , ( b ) p h a r m a c e u t i c a l c o m b i n a t i o n s a n d c o m p o s i t i o n s c o m p r i s i n g a c a r b i d o p a p r o d r u g a n d o r a n - d o p a p r o d r u g , a n d ( c ) m e t h o d s o f t r e a t i n g a r k i n s o n ' s d i s e a s e a n d a s s o c i a t e d c o n d i t i o n s c o m p r i s i n g a d m i n i s t e r i n g a c a r b i d o p a p r o d r u g a n d a n - d o p a p r o d r u g t o a s u b j e c t w i t h a r k i n s o n ' s d i s e a s e

NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS

Resumen de: WO2025215579A1

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

Nitrogen-Containing Heterocyclic Compounds

Resumen de: US2025320213A1

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

ANTIBODIES TO PYROGLUTAMATE AMYLOID-B AND USES THEREOF

Resumen de: US2025320286A1

The invention provides antibodies or antigen binding fragments thereof that bind to 3pE Aβ and methods of making and using the antibodies or antigen binding fragments thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other β-amyloid-related diseases.

2-(TERT-BUTYL)-4-METHYLPHENYL APPENDED 1,4-DIAZEPANE BASED NOVEL TFEB ACTIVATING COMPOUNDS AS AUTOPHAGY MODULATORS FOR NEURODEGENERATIVE DISORDERS INCLUDING ALZHEIMER'S DISEASE (AD)

Resumen de: WO2025217552A1

Provided are compounds for activating TFEB, the compounds being according to Formula (I) or Formula (II) as well as pharmaceutical compositions including such compounds and methods for using the compounds for the treatment of diseases and disorders.

PHARMACEUTICAL CRYSTAL HAVING LOW WATER SOLUBILITY, PREPARATION METHOD THEREFOR, AND USE THEREOF

Resumen de: WO2025213771A1

A pharmaceutical crystal having low water solubility, a preparation method therefor, and the use thereof. A crystal form I of pamoate of a compound Z has characteristic diffraction peaks at the diffraction angles 2θ of 9.9±0.2°, 10.7±0.2°, 12.1±0.2°, 14.9±0.2°, 17.3±0.2°, 19.4±0.2°, 20.7±0.2° and 23.1±0.2°. Compared with amorphous pamoate of the compound Z, said crystal has good stability, is free of polymorphic transformation, does not involve obvious increases of related substances, and has a low solubility. A production process therefor is simple and only uses water as a solvent in the whole process without the need of using an organic solvent. Using the crystal form I of pamoate of the compound Z for preparing a long-acting sustained-releasing pharmaceutical composition for Parkinson's disease can achieve a high drug encapsulation ratio and low burst release, and enables drug release of the composition in vivo to last for over two weeks, so that the frequency of drug administration to patients can be reduced, and the medication compliance is improved.

METHODS FOR REDUCING TAU EXPRESSION

Resumen de: US2025320493A1

Provided herein are methods of administering ISIS 814907 for ameliorating Alzheimer's disease, reducing Tau RNA, or reducing Tau protein in a human subject in need thereof. In certain embodiments, the Alzheimer's disease is mild Alzheimer's disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, and/or Alzheimer's Disease Dementia (e.g., Mild Alzheimer's Disease Dementia). In certain instances, methods are useful for ameliorating at least one symptom or hallmark of a disease or disorder associated with Tau protein. In certain instances, the disease or disorder associated with Tau protein is a neurodegenerative disease or disorder. In certain instances, the disease or disorder associated with Tau protein is Alzheimer's disease or Fronto-temporal Dementia (FTD). In certain embodiments, the Alzheimer's disease is mild Alzheimer's disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, and/or Alzheimer's Disease Dementia (e.g., Mild Alzheimer's Disease Dementia). In certain instances, the disease or disorder associated with Tau protein is a tauopathy. In certain instances, the disease or disorder associated with Tau protein is Frontotemporal Dementia with Parkinsonism-17 (FTDP-17), Progressive Supranuclear Palsy (PSP), Chronic Traumatic Encephalopathy (CTE), Corticobasal Ganglionic Degeneration (CBD), Pick Disease, Argyrophilic Grain Disease (AGD), Globular Glial Tauopathies, Epilepsy, and/or Dravet's Syndrome. Such symptoms or hallmarks include loss of

AAV VECTORS ENCODING SOD1-TARGETING ARTIFICIAL MIRNAS (AMI-RNA)

Resumen de: US2025320503A1

Aspects of the disclosure relate to compositions and methods for reducing expression or activity of superoxide dismutase 1 (SOD1) in a cell or subject. In some embodiments, the compositions, such as nucleic acid and viral vectors, comprise artificial microRNAs (amiRNAs) having a SOD1-targeting sequence positioned within a microRNA scaffold. In some embodiments, the compositions further comprise a human SMN1 promoter. In some aspects, the methods comprise administering a composition of the disclosure to a subject, for example a subject having amyotrophic lateral sclerosis (ALS).

MITOCHONDRIA-DERIVED MIRNA AND USE THEREOF IN SENESCENCE-RELATED DISEASE

Resumen de: WO2025213608A1

The present invention provides an miR 1978 inhibitor and use thereof in treating a senescence-related disease. The etiology of senescence-related diseases is proposed, and the overexpression of miR 1978 derived from the mitochondrial genome in cell line SHSY5Y is proven to give rise to decreased mRNA expression and protein levels of DHFR, KIF5C, and MSH3; as a result, SHSY5Y cell division is arrested in the G1 phase of the cell cycle, the number of cells in the G2/M phase is significantly reduced, and meanwhile, the number of apoptotic cells is increased. Compared with a control, cells containing miR1978 have different nuclear DNA methylation states. A plurality of Alzheimer's disease-related proteins, such as APP, Tau, p-Tau, and APOE, or Parkinson's disease-related proteins, such as α-synuclein, are increased in the SHSY5Y cell line containing miR 1978, etc.

DELAYED TIMED RELEASE PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR, AND USE THEREOF

Resumen de: EP4631499A1

A delayed timed release pharmaceutical composition, a preparation method therefor, and use thereof. The pharmaceutical composition comprises a tablet core. The tablet core comprises a drug-containing layer and a boosting layer stacked on the drug-containing layer. The drug-containing layer comprises a drug active ingredient. The drug active ingredient is levodopa or a derivative thereof, or a mixture of levodopa or a derivative thereof and a DOPA decarboxylase inhibitor, and accounts for 5-72.5 wt% of the content of the drug-containing layer. The pharmaceutical composition is a capsule-shaped tablet, can realize the effects of 1-3 h delayed release of the drug active ingredient and reaching a peak concentration at 6-10 h, can be used for reducing morning stiffness in patients with Parkinson's disease, and has good application prospects.

LOW DOSE HUMAN INTERLEUKIN-2 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS IN A SUBGROUP OF PATIENTS

Resumen de: WO2024121173A1

The present invention is in the field of amyotrophic lateral sclerosis (ALS) and relates to human interleukin-2 (IL-2) for use in the treatment of amyotrophic lateral sclerosis in a human subject, wherein each dose of human IL-2 administered to said subject is between 0.1 x106 to 3x106 international units (IU) and the subject has a low to medium concentration of p-NFH in cerebrospinal fluid (CSF p-NFH) or a low to medium concentration of NFL or NFM in cerebrospinal fluid, blood, serum or plasma before human IL-2 administration. The invention also relates to medical uses where the CSF p-NFH or CSF, blood, serum or plasma NFL or NFM concentration is used to select the best administration scheme or as a biomarker for stratified randomization of a cohort of ALS patients in the context of a clinical trial assessing the therapeutic efficiency of a candidate ALS treatment.

CBD METHOD FOR PRODUCING CANNABIDIOLCBD STRUCTURE ANALOGUES LINKED TO ALZHEIMER'S AND ELECTRONIC DEVICE PEFORMING THEREOF

Nº publicación: KR20250146107A 13/10/2025

Solicitante:

희래주식회사

Resumen de: KR20250146107A

본 개시의 일 관점에 따르면, 알츠하이머병과 연관된 칸나비디올(Cannabidiol, CBD) 유사체(structure analogue) 생성 방법은 약물 및 약물과 결합 가능한 단백질에 대한 정보를 포함하는 제1 데이터베이스 상에서, 상기 CBD와 연관된 약물-단백질 페어를 선별하는 단계; 상기 약물-단백질 페어에 포함된 단백질 중에서, 결합 친화도(binding affinity)를 기초로 상기 CBD와 결합 가능한 후보 단백질을 결정하는 단계; 질병 및 질병과 연관된 단백질에 대한 정보를 포함하는 제2 데이터베이스에 기초하여, 상기 후보 단백질 중에서 알츠하이머병과 연관된 표적 단백질을 식별하는 단계; 및 상기 표적 단백질 각각에 대하여, 생성형 모델을 기초로 CBD 유사체(structure analogue)를 생성하는 단계를 포함할 수 있다.